Reviews Carbidopa


No reviews yet.

Lodosyn Drug Description
LODOSYN®
(carbidopa) Tablets


When LODOSYN* (Carbidopa) is to be given to carbidopa-naive patients who
are being treated with levodopa, the two drugs should be given at the same
time, starting with no more than 20 to 25% of the previous daily dosage of
levodopa when given without LODOSYN (Carbidopa). At least twelve hours should
elapse between the last dose of levodopa and initiation of therapy with LODOSYN
(Carbidopa) and levodopa. See the WARNINGS and
DOSAGE AND ADMINISTRATION sections before initiating
therapy.

DRUG DESCRIPTION



What are the possible side effects of carbidopa (Lodosyn)?

Carbidopa alone is not associated with side effects. The following side effects are generally associated with carbidopa and levodopa therapy.
If you experience any of the following serious side effects, stop taking carbidopa and levodopa and seek emergency medical attention or contact your doctor immediately:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
uncontrolled movements of a part of the body;
...
Read All Potential Side Effects for Lodosyn »




Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white,
crystalline compound, slightly soluble in water, with a molecular weight of
244.3. It is designated chemically as (–)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene)
propanoic acid monohydrate. Its empirical formula is C10H14N2O4•H2O,
and its structural formula is:








LODOSYN (Carbidopa) tablets contain 25 mg of carbidopa. Inactive ingredients are cellulose, FD&C Yellow 6, magnesium stearate and starch.
Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.3.
Last reviewed on RxList: 10/3/2008




Lodosyn Drug Description
LODOSYN®
(carbidopa) Tablets


When LODOSYN* (Carbidopa) is to be given to carbidopa-naive patients who
are being treated with levodopa, the two drugs should be given at the same
time, starting with no more than 20 to 25% of the previous daily dosage of
levodopa when given without LODOSYN (Carbidopa). At least twelve hours should
elapse between the last dose of levodopa and initiation of therapy with LODOSYN
(Carbidopa) and levodopa. See the WARNINGS and
DOSAGE AND ADMINISTRATION sections before initiating
therapy.

DRUG DESCRIPTION



What are the possible side effects of carbidopa (Lodosyn)?

Carbidopa alone is not associated with side effects. The following side effects are generally associated with carbidopa and levodopa therapy.
If you experience any of the following serious side effects, stop taking carbidopa and levodopa and seek emergency medical attention or contact your doctor immediately:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
uncontrolled movements of a part of the body;
...
Read All Potential Side Effects for Lodosyn »




Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white,
crystalline compound, slightly soluble in water, with a molecular weight of
244.3. It is designated chemically as (–)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene)
propanoic acid monohydrate. Its empirical formula is C10H14N2O4•H2O,
and its structural formula is:








LODOSYN (Carbidopa) tablets contain 25 mg of carbidopa. Inactive ingredients are cellulose, FD&C Yellow 6, magnesium stearate and starch.
Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.3.
Last reviewed on RxList: 10/3/2008




Lodosyn Drug Description
LODOSYN®
(carbidopa) Tablets


When LODOSYN* (Carbidopa) is to be given to carbidopa-naive patients who
are being treated with levodopa, the two drugs should be given at the same
time, starting with no more than 20 to 25% of the previous daily dosage of
levodopa when given without LODOSYN (Carbidopa). At least twelve hours should
elapse between the last dose of levodopa and initiation of therapy with LODOSYN
(Carbidopa) and levodopa. See the WARNINGS and
DOSAGE AND ADMINISTRATION sections before initiating
therapy.

DRUG DESCRIPTION



What are the possible side effects of carbidopa (Lodosyn)?

Carbidopa alone is not associated with side effects. The following side effects are generally associated with carbidopa and levodopa therapy.
If you experience any of the following serious side effects, stop taking carbidopa and levodopa and seek emergency medical attention or contact your doctor immediately:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
uncontrolled movements of a part of the body;
...
Read All Potential Side Effects for Lodosyn »




Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white,
crystalline compound, slightly soluble in water, with a molecular weight of
244.3. It is designated chemically as (–)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene)
propanoic acid monohydrate. Its empirical formula is C10H14N2O4•H2O,
and its structural formula is:








LODOSYN (Carbidopa) tablets contain 25 mg of carbidopa. Inactive ingredients are cellulose, FD&C Yellow 6, magnesium stearate and starch.
Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.3.
Last reviewed on RxList: 10/3/2008




Lodosyn Drug Description
LODOSYN®
(carbidopa) Tablets


When LODOSYN* (Carbidopa) is to be given to carbidopa-naive patients who
are being treated with levodopa, the two drugs should be given at the same
time, starting with no more than 20 to 25% of the previous daily dosage of
levodopa when given without LODOSYN (Carbidopa). At least twelve hours should
elapse between the last dose of levodopa and initiation of therapy with LODOSYN
(Carbidopa) and levodopa. See the WARNINGS and
DOSAGE AND ADMINISTRATION sections before initiating
therapy.

DRUG DESCRIPTION



What are the possible side effects of carbidopa (Lodosyn)?

Carbidopa alone is not associated with side effects. The following side effects are generally associated with carbidopa and levodopa therapy.
If you experience any of the following serious side effects, stop taking carbidopa and levodopa and seek emergency medical attention or contact your doctor immediately:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
uncontrolled movements of a part of the body;
...
Read All Potential Side Effects for Lodosyn »




Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white,
crystalline compound, slightly soluble in water, with a molecular weight of
244.3. It is designated chemically as (–)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene)
propanoic acid monohydrate. Its empirical formula is C10H14N2O4•H2O,
and its structural formula is:








LODOSYN (Carbidopa) tablets contain 25 mg of carbidopa. Inactive ingredients are cellulose, FD&C Yellow 6, magnesium stearate and starch.
Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.3.
Last reviewed on RxList: 10/3/2008




Lodosyn Drug Description
LODOSYN®
(carbidopa) Tablets


When LODOSYN* (Carbidopa) is to be given to carbidopa-naive patients who
are being treated with levodopa, the two drugs should be given at the same
time, starting with no more than 20 to 25% of the previous daily dosage of
levodopa when given without LODOSYN (Carbidopa). At least twelve hours should
elapse between the last dose of levodopa and initiation of therapy with LODOSYN
(Carbidopa) and levodopa. See the WARNINGS and
DOSAGE AND ADMINISTRATION sections before initiating
therapy.

DRUG DESCRIPTION



What are the possible side effects of carbidopa (Lodosyn)?

Carbidopa alone is not associated with side effects. The following side effects are generally associated with carbidopa and levodopa therapy.
If you experience any of the following serious side effects, stop taking carbidopa and levodopa and seek emergency medical attention or contact your doctor immediately:

an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives);
uncontrolled movements of a part of the body;
...
Read All Potential Side Effects for Lodosyn »




Carbidopa, an inhibitor of aromatic amino acid decarboxylation, is a white,
crystalline compound, slightly soluble in water, with a molecular weight of
244.3. It is designated chemically as (–)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxybenzene)
propanoic acid monohydrate. Its empirical formula is C10H14N2O4•H2O,
and its structural formula is:








LODOSYN (Carbidopa) tablets contain 25 mg of carbidopa. Inactive ingredients are cellulose, FD&C Yellow 6, magnesium stearate and starch.
Tablet content is expressed in terms of anhydrous carbidopa which has a molecular weight of 226.3.
Last reviewed on RxList: 10/3/2008





Other reviews about Carbidopa on wordpress

Buy Carbidopa Online Order Cheap Carbidopa Generic Purchase Discount Without Prescription
  by worlddnews
FOLLOW THIS LINK FOR ENTER TO TRUSTED & REPUTABLE ONLINE DRUGSTORE WHERE YOU CAN GET ALL QUALIFIED INFORMATION ABOUT Carbidopa ONLINE     Some medications that can induce anxiety can cause […]


SINEMET® (carbidopa-levodopa) Tablets
  by kanlayanee
[caption id="" align="alignnone" width="288" caption="SINEMET CR 50/200 TABLET SA"][/caption] Levodopa is the levorotatory isomer of dihydroxyphenylalanine and the metabolic precursor of dopamine, and carbidopa is a decarboxylase inhibitor that […]


Depomed Initiates Phase I Trial for DM-1992 Program in Parkinson’s Disease Following Positive Results of Preclinical Studies Sponsored by The Michael J. Fox Foundation
  by finestitcher
CentralDaily.com / Tuesday, Feb. 17, 2009 MENLO PARK, Calif. — Depomed, Inc. (NASDAQ/DEPO) today announced that it has dosed the first patient in a Phase I trial for […]


Orion Corporation Withdraws Its Application For An Extension Of Indication for Stalevo (levodopa/carbidopa/entacapone)
  by finestitcher
PharmaLive, March 10, 2009 LONDON, March 10, 2009--The European Medicines Agency (EMEA) has been formally notified by Orion Corporation of its decision to withdraw its application for an extension […]


Annotation 6...
  by soxbullsbearsfan
Mike Schutt Professor Vander Lei English 102 12 March 2010 Annotation 6 K, Lo, et al. "Management of Parkinson's Disease: current treatments, recent advances, and future development." Biomedical (2008): 529-43. Web. 7 Mar. […]


Annotation 7........
  by soxbullsbearsfan
Mike Schutt Professor Vander Lei English 102 12 March 2010 Annotation 7 The Michael J Fox Foundation for Parkinson's Research. Michael J Fox, 2010. Web. 7 Mar. 2010. <http://www.michaeljfox.org/index.cfm>.            Drugs for PD -Levadopa/Carbidopa -Dopamine Agonists -MAO-inhibitors -COMT-inhibitors Surgery -Deep […]


Drug Information Update - Ongoing Safety Review of Stalevo (entacapone/carbidopa/levodopa) and possible development of Prostate Cancer
  by neurologist
The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation […]


Drug Cards: Abilify / Seroquel / Aricept / Sinemet
  by roselynlucas
Here are new drug cards I've finished. You can edit these as needed. I didn't include every single info of each drug. The file is already formated and ready for […]


Parkinson's Disease
  by purpleastrid
Does Parkinson's disease? Parkinson's disease causes problems in brain nerve cells responsible for controlling muscle movement. nerve cells that produce a chemical called Dopamine normally sends signals that help […]


FDA MedWatch - Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk
  by irbtipoftheweek
Issue: FDA notified healthcare professionals that it is evaluating clinical trial data that suggest patients taking Stalevo (a combination of carbidopa/levodopa and entacapone) may be at an increased […]



Other reviews about Carbidopa on web:

Carbidopa (Lodosyn) is a drug given to people with Parkinson's disease in order to inhibit peripheral metabolism of levodopa. Carbidopa - Wikipedia, the free encyclopedia


Physician reviewed carbidopa patient information - includes carbidopa description, dosage and directions. carbidopa medical facts from Drugs.com


Carbidopa Brand names: Lodosyn® Chemical formula: Español: Carbidopa, Tableta oral Carbidopa Oral tablet What is this medicine? CARBIDOPA (kar bi Carbidopa: Information from Answers.com


Carbidopa/levodopa is the combination of carbidopa and levodopa and is used to treat Parkinson's disease and Dopa-Responsive Dystonia (DRD). It is sold under several brand names ... Carbidopa/levodopa - Wikipedia, the free encyclopedia


All about Carbidopa. View complete and up to date Carbidopa information - part of the Drugs.com trusted medication database. Carbidopa Facts and Comparisons at Drugs.com


Explains neurology (brain and nerve) conditions; includes symptoms, causes, medications, diagnosis, treatments, prevention, and prognosis information. levodopa-carbidopa - Neurology (Brain and Nerve) Conditions ...


Carbidopa Review And Carbidopa Levodopa Information ... Click on the image below to Buy Carbidopa Levodopa Online ! Carbidopa Carbidopa Levodopa Review And Information


Consumer information about the medication CARBIDOPA - ORAL (Lodosyn), includes side effects, drug interactions, recommended dosages, and storage information. Read more about ... CARBIDOPA - ORAL (Lodosyn) side effects, medical uses, and drug ...


Learn about the prescription medication Sinemet (Carbidopa-Levodopa), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Sinemet (Carbidopa-Levodopa) Drug Information: Uses, Side Effects ...


Carbidopa is a prescription drug used to treat Parkinson's disease and Parkinsonism due to other causes. This eMedTV page covers carbidopa uses in more detail, describes the ... Carbidopa





Featured Reviews

Reviews Sinequan

Sinequan Drug Description SINEQUAN® (doxepin HCl) Capsules and Oral Concentrate Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in...
Read More  |  Review This
Reviews Lubiprostone

Amitiza Drug Description Amitiza® (lubiprostone) Capsules DRUG DESCRIPTION What are the possible side effects of lubiprostone (Amitiza)? Stop using lubiprostone and get emergency medical help if you have any of these signs...
Read More  |  Review This
Reviews Tygacil

Tygacil Drug Description TYGACIL® (tigecycline) for Injection for Intravenous Use DRUG DESCRIPTION What are the possible side effects of tigecycline (Tygacil)? Get emergency medical help if you have any of these signs of an...
Read More  |  Review This
Reviews Diucardin

Diucardin Drug Description DRUG DESCRIPTION Diucardin (hydroflumethiazide) is an oral thiazide (benzothiadiazide) diuretic-antihypertensive agent. Diucardin is available as 50 mg tablets for oral administration. Chemical name:  3,4...
Read More  |  Review This
Reviews Olmesartan Medoxomil Amlodipine Hydrochlorothiazide Tablets

Tribenzor Drug Description Tribenzor™ (olmesartan medoxomil, amlodipine, hydrochlorothiazide) Tablets WARNING AVOID USE IN PREGNANCY When pregnancy is detected, discontinue Tribenzor as soon as possible. Drugs that act directly...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....